



Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis (dRTA)

ADV7103 could potentially be the first approved treatment for dRTA, a renal orphan disease

Nîmes, France, 20th September, 2017 – Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today the presentation of a poster on the company's lead product ADV7103. The poster will be presented at the 9th European Paediatric Formulation Initiative (EuPFI) conference in Warsaw on 20-21 September 2017.

The poster, entitled "*Innovative age-adapted formulation for treatment of dRTA with a 12-hour coverage*", is displayed in the poster hall at the EuPFI conference and presented by author Caroline Roussel-Maupetit, Director of Operations and co-founder of Advicenne.

ADV7103 is an innovative paediatric-friendly twice a day product which has recently shown positive results in a pivotal phase III study in children and adults with dRTA. ADV7103 has been designed to address the disease both in children and adults for whom the disease has a genetic origin, as well as for adults who may have acquired the condition as a result of autoimmune disease.

Caroline Roussel-Maupetit, Director of Operations and cofounder of Advicenne, commented, "*We are excited to have the opportunity to present our innovative research in nephrology. The data being presented today and the positive phase III results we have announced recently with ADV7103 reflects our ability to leverage our development expertise and unwavering commitment to patients to deliver paediatric-friendly therapeutics for the treatment of orphan renal diseases for which there are currently no approved treatment options.*"

The European Commission granted orphan drug designation (ODD) to ADV7103 for the treatment of dRTA in June 2017.

For further information, please contact:

Advicenne

LA Granier, S Delbaere, J Rachline

info@advicenne.com

+33 (0)4 66 05 54 20

Citigate Dewe Rogerson

David Dible, Sylvie Berrebi, Marine Perrier

advicenne@citigatedr.co.uk

+44 (0) 20 7638 9571

About distal Renal Tubular Acidosis (dRTA)

dRTA is a disease that occurs when the kidneys do not properly remove acids from the blood into the urine. As a result, too much acid remains in the blood which generates an unbalanced pH that can lead to failure to thrive and rickets (a condition that affects bone development in children) as well as a range of additional clinical disorders such as a potassium deficiency (hypokalaemia) in the blood serum which alters the function of several organs and most prominently affects the



cardiovascular system. In addition, a high concentration of calcium in the blood and urine (hypercalcemia and hypercalciuria respectively) can lead to kidney stones and calcinosis that can potentially cause renal impairment, ultimately leading to renal failure. The disease, either genetic (usually occurring during childhood) or acquired as a result of autoimmune disease, is estimated to affect approximately 30 000 to 50 000 patients in Europe. Current standard of care are usually various unapproved products administered every four to six hours to attempt to re-balance the body's pH and to normalise blood potassium level.

About Advicenne

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company's most advanced product is ADV7103 which has shown positive results in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). In addition to ADV7103, the Company has a portfolio of products targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.

Additional information about Advicenne is available through its website:

<http://advicenne.com/en/>

Disclaimer

This press release contains information regarding clinical development of ADV7103.